07 May 2020
Register for free to join
The Covid19 crisis has wreaked havoc across the entire world, with impacts both personal and economical for everyone. As the search for vaccines goes on, many are looking to the pharmaceutical industry for leadership and support, however, life for Pharma has been as disrupted as it has been for other companies. What should we therefore expect? We discuss with Riccardo Braglia what impact the crisis has had on his company, Helsinn Group, and moreover, what comes next.
With over 35 years of international experience in the pharmaceutical industry, Mr. Braglia will share his unique insights on the future of health, digital and leadership in today's fragile yet resilient world.
Riccardo Braglia, Helsinn Group’s Vice Chairman and CEO, Managing Director and Member of Helsinn Holding’s Board of Directors, Switzerland and Executive Committee for Helsinn Group’s strategic management, has a wealth of over 35 years of international experience in the pharmaceutical industry. Mr. Braglia heads the family-run, privately-owned pharmaceutical company, the Helsinn Group, founded in 1976, with a worldwide presence and focus on cancer therapeutics and supportive care, which is strongly committed to improving the everyday lives of people with cancer.
Mr. Braglia is Board Member of Helsinn Healthcare, Switzerland, Helsinn Advanced Synthesis, Switzerland, Helsinn Birex Pharmaceuticals, Ireland, Helsinn Pharmaceuticals (Beijing), China. He is Chairman of Helsinn Therapeutics, USA, as well as Président Directeur Général – Gérant Associé of Helsinn International Services, Monaco, Principality of Monaco and Chairman of Helsinn Investment Fund, Luxembourg.
Helsinn is a privately-owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com
The first and only
Swiss Association of
Centro Galleria 1 A
6928 Manno CH
@ DAGORA TECH HUB
T. +41 (0) 91 210 47 36
VAT no.: CHE-485.124.256 IVA
T. +41 44 500 21 73
Blue Box, Chemin du Pré-Fleuri 3
1228 Plan-les-Ouates CH
T. +41 (0) 22 510 71 03
@ Fongit Foundation